Due to mutating viral strains, the potential benefits of this COVID-19 drug no longer outweigh the risks.
Due to mutating viral strains, the potential benefits of this COVID-19 drug no longer outweigh the risks.
Vaccine candidates from Pfizer-BioNTech and Moderna received EUAs, as did the first at-home test that delivers results in 30 minutes, and two treatments for the virus.
Veklury is approved for hospitalized patients, while bamlanivimab is being investigated in mild-to-moderate cases of COVID-19.
The malaria drug loses an EUA for COVID-19, while the FDA warns of drug interactions that can reduce antiviral effectiveness.
